Brainstorm Cell Therapeutics I Stock Price, News & Analysis

BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced that Stacy Lindborg, Ph.D., will present at the 2020 Cell & Gene Meeting on the Mesa, held virtually from October 12-16, 2020. The presentation is available on-demand for registered participants. The conference will showcase over 80 presentations by various companies highlighting advancements in cell therapy and gene therapy. BrainStorm’s NurOwn technology is focused on treating neurodegenerative diseases, including a Phase 3 trial for ALS and a Phase 2 trial for progressive MS, supported by FDA approvals.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) will hold a conference call on October 15, 2020, at 8:00 a.m. EDT to discuss third-quarter financial results for the period ending September 30, 2020, and provide a corporate update. The call will feature CEO Chaim Lebovits, alongside key executives who will answer shareholder questions. Participants can submit questions until October 13, 2020. The company is noted for its NurOwn technology, which targets neurodegenerative diseases and has several ongoing clinical trials.

On September 30, 2020, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) presented a poster on the Phase 3 clinical trial design of NurOwn® for ALS at the virtual Annual Northeast ALS Meeting. The trial is designed to evaluate the effects of NurOwn® on rapidly progressing ALS patients, building on promising Phase 2 results. The study aims to confirm the efficacy of NurOwn® and assess its duration through repeated administrations. Topline data from the trial is expected in Q4 2020, marking a significant step towards potential FDA approval.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the appointment of William K. White as Senior Vice President, Head of Market Access and Pricing. With over 25 years of experience in product commercialization, White aims to ensure market access for NurOwn®, currently in a Phase 3 trial for ALS. CEO Chaim Lebovits emphasized the importance of White's background in securing patient access to innovative therapies, crucial for the potential FDA approval of NurOwn®. The company is focused on bringing revolutionary stem cell treatments to patients suffering from neurodegenerative diseases.

Brainstorm Cell Therapeutics (NASDAQ: BCLI) announced the granting of a new patent by the Japanese Patent Office for its method of generating mesenchymal stem cells secreting neurotrophic factors, crucial for treating neurodegenerative diseases. The patent covers key neurotrophic factors such as BDNF, GDNF, HGF, and VEGF. This development strengthens Brainstorm’s intellectual property portfolio, enhances its ability to secure commercial partnerships in Japan, and supports its ongoing Phase 3 trial for ALS treatment. The company aims to leverage this patent for strategic growth and market presence.

On August 25, 2020, BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the acceptance of a clinical abstract showcasing a correlation between MRI measures and functional improvements in patients with progressive multiple sclerosis (MS). This data will be presented at the MSVirtual2020 meeting on September 11-13. The analysis involved 48 participants and revealed significant differences in MRI data between those with improved versus stable or worsening function, specifically using the 9-hole peg test and timed-25-foot-walk metrics. CEO Chaim Lebovits emphasized the potential implications for clinical outcomes in their ongoing Phase 2 trial of NurOwn®.

On August 19, 2020, BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced the publication of a manuscript regarding the effects of its NurOwn stem cell therapy on T and B regulatory cells in ALS. The research highlighted significant findings, including a notable reduction in inflammatory biomarkers and increased circulating T regulatory cells in previous clinical studies. The preclinical experiments demonstrated a decrease in interferon-g secretion and induction of regulatory cells, which may support NurOwn's therapeutic potential in ALS and other neuroinflammatory diseases.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that Dr. Ralph Kern will present a corporate overview at the 40th Annual Canaccord Genuity Growth Conference, held virtually from August 11-13, 2020. One-on-one meetings with institutional investors will also be available on the presentation day. The event will take place on August 13, 2020, at 3:30 PM ET, with a webcast accessible for viewing. BrainStorm develops adult stem cell therapies, notably its MSC-NTF cells for ALS, which have received Orphan Drug status from the FDA and EMA. Phase 3 trials are ongoing, aiming for FDA approval.

BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported its Q2 2020 financial results, highlighting a net loss of $7.39 million, up from $4.90 million in Q2 2019. Despite COVID-19 challenges, the firm completed enrollment in its Phase 3 ALS trial, with data expected by November 2020. BCLI is also advancing its NurOwn platform into new areas, including Alzheimer's, with a Phase 2 trial planned in Europe. The company has approximately $37.5 million in available funding as of July 31, 2020, reflecting growth from prior periods.